Immune checkpoint blockade (ICB) immunotherapy has garnered extensive interest, as targeting immune checkpoint receptors, such as PD-1, PD-L1, CTLA4, and LAG-3, effectively suppresses immunosuppressive pathways in the TME in many cancer types [193,194]. The gene discussed is CD274; the disease is cancer.